Orelabrutinib in the Treatment of Relapsed/Refractory AIHA
NCT07453368
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Autoimmune Hemolytic Anemia (AIHA)
Interventions
DRUG:
Orelabrutinib-50
DRUG:
Orelabrutinib-100
DRUG:
Orelabrutinib-150
Sponsor
Peking Union Medical College Hospital